Dr. Moroney on the Evaluation of COM701 Plus BMS-986207 and Nivolumab in Ovarian Cancer

John Moroney, MD, associate professor, Obstetrics and Gynecology, associate professor, Medicine, the University of Chicago, discusses the evaluation of COM701 plus BMS-986207 and nivolumab (Opdivo) in platinum-resistant ovarian cancer.

A phase 1/2 trial (NCT04570839) is evaluating the combination of COM701 plus BMS-986207 and nivolumab in patients with advanced solid tumors, including ovarian cancer. Data were presented from 20 patients with platinum-resistant epithelial ovarian cancer at the 2022 ESMO Immuno-Oncology Annual Congress.

Four patients achieved confirmed durable and deep partial responses for an overall response rate of 20%, Moroney says. Immune checkpoint inhibitors have historically produced low response rates in ovarian cancer, so these data are encouraging, Moroney adds.

Moreover, the responders were also heavily pretreated patients, Moroney continues. The ability to demonstrate activity with nivolumab in this combination warrants further investigation in this setting, Moroney concludes.